These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30003760)

  • 1. Is it rational to extend the duration of preventive endocrine treatment in hormone receptor positive ductal carcinoma in situ?
    Altundag K
    J BUON; 2018; 23(3):835. PubMed ID: 30003760
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
    Altundag K; Bulut N; Sari E; Harputluoglu H
    Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
    [No Abstract]   [Full Text] [Related]  

  • 3. Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
    Nye L; Rademaker A; Gradishar WJ
    Clin Breast Cancer; 2017 Jul; 17(4):e185-e189. PubMed ID: 28185739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
    Osin P; Crook T; Powles T; Peto J; Gusterson B
    Lancet; 1998 May; 351(9114):1487. PubMed ID: 9605807
    [No Abstract]   [Full Text] [Related]  

  • 5. Uterine sarcoma after tamoxifen therapy for breast cancer.
    Samuji M; O'Sullivan R; Shireen R
    Ir Med J; 2013 Sep; 106(8):246. PubMed ID: 24282897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials-Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy.
    Sun SX; Kuerer HM
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):804-805. PubMed ID: 31654165
    [No Abstract]   [Full Text] [Related]  

  • 7. A new model for ductal carcinoma in situ suggests strategies for treatment.
    Gullick WJ
    Breast Cancer Res; 2002; 4(5):176-8. PubMed ID: 12223119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining the use of endocrine therapy for ductal carcinoma in situ.
    Morrow M
    J Clin Oncol; 2012 Apr; 30(12):1249-51. PubMed ID: 22393104
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenge in the treatment of estrogen-receptor-negative ductal carcinoma in situ.
    Altundag K
    J Clin Oncol; 2005 Jul; 23(19):4469-70. PubMed ID: 15994163
    [No Abstract]   [Full Text] [Related]  

  • 10. [Significance of HER2 testing in breast cancer].
    Ni YB; Yang WJ; Bu H; Zheng H
    Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):76-8. PubMed ID: 21426800
    [No Abstract]   [Full Text] [Related]  

  • 11. Endocrine therapy in DCIS: how do we proceed?
    Dixon JM; Jane Macaskill E
    Breast J; 2012; 18(4):295-8. PubMed ID: 22759092
    [No Abstract]   [Full Text] [Related]  

  • 12. [Is low-dose tamoxifen an effective therapy for breast carcinoma in situ?].
    Ivanova OA; Zhil'tsova EK; Barash NIu; Ivanov VG; Ermachenkova AM
    Vopr Onkol; 2011; 57(5):601-3. PubMed ID: 22238929
    [No Abstract]   [Full Text] [Related]  

  • 13. Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
    Johnston SR
    Lancet; 2016 Feb; 387(10021):819-21. PubMed ID: 26686312
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lobular carcinoma-in-situ and ductal hyperplasia of breast].
    Fu L
    Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):4-7. PubMed ID: 16608640
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
    Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
    Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ductal carcinoma in situ.
    Venniyoor A
    Aust Fam Physician; 2006 May; 35(5):278-9; author reply 279. PubMed ID: 16708448
    [No Abstract]   [Full Text] [Related]  

  • 17. Trastuzumab not for ductal carcinoma in situ?
    Nahleh Z; Namakydoust A; Bakkar R; Bishop J
    Anticancer Drugs; 2007 Nov; 18(10):1231-5. PubMed ID: 17893526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
    Chlebowski RT; Col N
    Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.